The first World Humanoid Robot Games have concluded in Beijing with more than 500 androids alternating between jerky tumbles and glimpses of real power as they took part in events ranging from the 100m (109-yard) hurdles to kung fu.
Two hundred eighty robotics teams from 16 countries competed at the Chinese capital’s National Speed Skating Oval, built for the 2022 Winter Olympics.
Events included traditional sports such as athletics and basketball as well as practical tasks such as medicine categorisation and cleaning.
“I believe in the next 10 years or so, robots will be basically at the same level as humans,” 18-year-old spectator Chen Ruiyuan said.
Human athletes might not be quaking in their boots just yet.
At one of the first events on Friday, five-a-side football, 10 robots the size of seven-year-olds shuffled around the pitch, often getting stuck in a scrum or falling over en masse.
However, in a 1,500m (nearly 1-mile) race, domestic champion Unitree’s humanoid stomped along the track at an impressive clip, easily outpacing its rivals.
The fastest robot finished in six minutes, 29.37 seconds, a far cry from the human men’s world record of 3:26.00.
One mechanical racer barrelled straight into a human operator. The robot remained standing while the human was knocked flat although did not appear to be injured.
Robot competitions have been held for decades, but the 2025 World Humanoid Robot Games is the first to focus specifically on robots that resemble human bodies, organisers said.
The Chinese government has poured support into robotics, hoping to lead the industry.
Beijing has put humanoids at the “centre of their national strategy”, the International Federation of Robotics wrote in a paper released on Thursday.
“The government wants to showcase its competence and global competitiveness in this field of technology,” it added.
In March, China announced plans for a one-trillion-yuan ($139bn) fund to support technology start-ups, including those in robotics and artificial intelligence.
The country is already the world’s largest market for industrial robots, official statistics showed, and in April, Beijing held what organisers called the world’s first humanoid robot half-marathon.
With coal accounting for 54% of Asia’s power mix last year, the region faces a significant challenge in meeting its net-zero ambitions. In a bid to cut emissions, several Asian countries are turning to ammonia for power generation, particularly through co-firing, blending low-carbon ammonia with coal or natural gas. Rystad Energy expects China, Indonesia, Japan, and South Korea to emerge as key hubs for this transition. However, a sizeable supply gap remains, with about 8.8 million tonnes per annum (Mtpa) of ammonia needed to meet 2030 targets.
Having relied on coal for decades, Asia lacks both the policy frameworks and the market demand needed to justify investment in infrastructure for ammonia as an energy source. Countries such as Japan and South Korea also face resource constraints, whether limited natural gas or insufficient renewable capacity, that hinder domestic production of clean ammonia. To meet net-zero goals, they will need to import clean ammonia from overseas, enabling coal replacement as a baseload power source while safeguarding energy security and affordability.
Ammonia co-firing is currently expensive, mainly due to the high costs associated with low-carbon hydrogen production, ammonia conversion and transportation. However, countries in Asia appear willing to tackle this challenge and advance their co-firing plans. Assuming a low-carbon hydrogen price of $5 per kilogram, which corresponds to an ammonia price of $1,000 per tonne, Rystad Energy estimates that the levelized cost of electricity for a 10% ammonia blend will be about 50% higher than coal-only generation. This indicates that costs must be tackled through innovation, economies of scale, or the implementation of a meaningful carbon price to make ammonia co-firing competitive.
While hydrogen and ammonia are set to play a growing role in decarbonizing Asia’s power sector, much of the progress hinges on foreign partnerships and long-term offtake agreements. Even with high costs associated with hydrogen, our data shows that ammonia demand from power generation is expected to grow ninefold by 2030. However, without firm offtake commitments and accelerated development of critical import infrastructure, this growth could stall. While several key Asian players are already in discussions with international partners to secure ammonia supply, progress on import terminals and co-firing capabilities must speed up,
Learn more with Rystad Energy’s Hydrogen Solution.
While Japan and Indonesia moved early to explore ammonia co-firing for power generation, China has taken a later but more decisive approach by embedding it as a decarbonization strategy in its National Development and Reform Commission (NDRC) 2024-2027 Action Plan. China is moving directly to national targets before large-scale feasibility trials. Starting in 2027, coal plants that are upgraded or newly commissioned must cut emissions by half compared to 2023 levels, with China planning to implement 10% co-firing of biomass and green ammonia alongside carbon capture, utilization and storage (CCUS) technologies.
If ammonia co-firing proves viable, it could be vital to meeting the nation’s goals of peaking emissions by 2030 and achieving carbon neutrality by 2060. However, it remains uncertain how many plants will adopt the technology. Given the size of China’s significant coal power generation fleet, it is likely that the roll-out of ammonia co-firing will take more than the targeted two years, especially when existing coal power plants will have to be retrofitted to accommodate the technology.
Due to abundant renewable resources in Inner Mongolia, China is well-positioned to produce low-carbon hydrogen and ammonia at scale, giving it an advantage compared to regional peers. This year, Envision Energy commissioned the world’s largest green ammonia plant in Chifeng, Inner Mongolia, with an initial capacity of 0.32 Mtpa and plans to expand to 1.5 Mtpa by 2028. As deal-making accelerates China could bolster its role as a dependable ammonia supplier for the region and pave the way for exports, though the required volumes still remain unclear.
South Korea is also looking to back hydrogen-for-power by 2029, with the country’s Ministry of Trade, Industry and Energy (MOTIE) having launched its second clean hydrogen power generation auction. Winning bidders, to be selected later this year, must begin generating power using hydrogen or derivatives such as ammonia by 2029 under a 15-year contract covering 3 terawatt-hours (TWh) of electricity. While this is 3.5 TWh less than the inaugural round, Rystad Energy estimates that producing this volume will still require around 200,000 tonnes of low-carbon hydrogen each year.
In the 2024 auction, the world’s first, MOTIE reported participation from only six power plants out of roughly 59 nationwide. Despite the limited response, only one plant met MOTIE’s evaluation criteria, which considered factors such as bid price and alignment with the country’s Clean Hydrogen Portfolio Standards (CHPS). MOTIE ultimately awarded Korea Southern Power (KOSPO) 750 gigawatt-hours at its Samcheok power plant, representing just 11.5% of the total volume on offer.
To encourage greater participation in this year’s auction, MOTIE is introducing two new mechanisms: an exchange rate-linked settlement system and a hydrogen volume borrowing system. Unlike the 2024 auction, which settled prices in South Korean won and exposed participants to currency risk from USD fluctuations, the upcoming auction will link power price settlements to the exchange rate, helping to mitigate this risk. The volume borrowing system allows power generators to borrow hydrogen volumes from the following year in advance, complementing the existing carryover system for unused volumes. Together, these changes offer generators increased flexibility to manage unplanned events or maintenance.
Japan, an early adopter of ammonia co-firing, has also made significant progress in 2025. The nation has secured key contracts and attracted foreign investment to maintain a steady supply of low-carbon ammonia, planning to source blue ammonia from the US and green ammonia from China and India to scale up and address domestic supply shortages. Early next year, Japan will also announce the winners of its contract for difference program, which is expected to provide additional support for its ammonia-for-power ambitions and help the country meet its emissions targets.
Contacts
Minh Khoi Le Head of Hydrogen Research Phone: +47 24 00 42 00 Minh.khoi.le@rystadenergy.com
Rystad Energy is a leading global independent research and energy intelligence company dedicated to helping clients navigate the future of energy. By providing high-quality data and thought leadership, our international team empowers businesses, governments and organizations to make well-informed decisions.
Our extensive portfolio of products and solutions covers all aspects of global energy fundamentals, spanning every corner of the oil and gas industry, renewables, clean technologies, supply chain and power markets. Headquartered in Oslo, Norway, with an expansive global network, our data, analysis, advisory and education services provide clients a competitive edge in the market.
The Ahmedabad Marathon 2025 will be held on November 30, with the start and finish point at the Sabarmati Riverfront, the organisers announced on Monday.
Registrations for all race categories – full marathon, half marathon, 10km run and 5km run – opened on August 15 and will remain open in the lead-up to the event.
Since its inception in 2017, the Ahmedabad Marathon has been held annually. Over the years, the event has grown into one of the country’s premier running festivals, attracting participants from across India.
In 2022, the Ahmedabad Marathon was listed on the Global Marathon Event List by the Association of International Marathons and Distance Races (AIMS). The race also holds certification from the Athletics Federation of India (AFI).
The route showcases some of Ahmedabad’s most iconic landmarks, including the Atal Bridge, Gandhi Ashram and Ellis Bridge, making it one of the most picturesque running experiences in the country.
In its previous edition in 2024, around 20,000 runners took part in the marathon, with more than 3,000 defence personnel joining in.
The central theme of the marathon continues to be Run4OurSoldiers – a tribute to the service and sacrifices of the Indian Armed Forces.
A major portion of the proceeds from the event goes for the welfare of the armed forces.
At the last edition, Gyan Babu won the men’s open full marathon title in Ahmedabad while Jyoti Gawate was crowned the women’s champion.
Isaac Health said it raised $10.5 million in a Series A round led by local venture firm Flare Capital Partners, bringing total capital raised to $16.3 million and setting up a national push to scale its AI-driven memory clinic.
According to the company and investor statements, new backers Industry Ventures and New York-based Black Opal Ventures participated, while prior investors who participated included: New York’s Meridian Street Capital and Primetime Partners, and Manhattan Beach, Calif.-based B Capital. The funding is intended to expand partnerships with payers and health systems, and broaden a virtual model the company says is now available in all 50 states.
“On the growth front, we’ve added a number of new partnerships. We’ve really crystallized our go-to-market fit and strategy,” Isaac Health co-founder and CEO Julius Bruch told Fierce Healthcare. “We are squarely focused on health plans, both on Medicaid and Medicare primarily, but also covering health systems. That’s where we see really the strength of Isaac Health pay out the most.”
The raise comes amid a mounting public-health challenge, with the Alzheimer’s Association saying millions of older Americans live with Alzheimer’s and related dementias. Isaac Health says patients can face average waits of about three years for specialist appointments. The delays, the company argues, cost critical intervention windows, and increase emergency and hospital use.
“Our health system isn’t equipped for the scale and complexity of these needs,” said Dr. Joel Salinas, Isaac Health’s chief medical officer and co-founder.
Isaac Health positions itself as a neurologist-led, AI-enabled platform that combines remote screening, assessment, treatment and care management. The company claims patented screening algorithms and predictive machine learning can detect diverse cognitive conditions.
In a pilot study, Isaac Health reports that 73% of patients showed improved neurocognitive function at six months and 92% met short-term cognitive improvement goals within three weeks. The study has not been peer reviewed.
Flare Capital said its investment is a bet on scaling virtual neurology and driving return through better diagnosis and management, particularly as disease-modifying Alzheimer’s therapies enter clinical practice and payers seek value-based care solutions.
Isaac Health plans to use the new fund to improve virtual care infrastructure, enhance AI-driven detection and predictive clinical decision support, and to measure outcomes and optimize care pathways. The strategy mirrors broader market moves to combine digital-first care delivery with specialty expertise to shrink geographic and socioeconomic access gaps.
The Pakistan Hockey Federation (PHF) has been given 48 hours to confirm whether it will send a team to India for the upcoming Asia Cup, scheduled to begin in Rajgir, Bihar, on 29 August. If it fails to respond, Bangladesh will be named as a replacement in the eight-team tournament, according to Hockey India (HI)
Despite the Indo-Pak political tensions post Operation Sindoor, the Government of India gave a green light for Pakistan to travel to Bihar for the Asia Cup 2025, keeping the Olympic charter in mind and also said it would provide visas to the Pakistan hockey contingent.
However, the PHF has reportedly refused to travel, citing security concerns. Although Bangladesh has already been approached, the hosts are still waiting two days before announcing the replacement. “The Indian government has already said that it is willing to provide visas to Pakistani players,” a HI official told PTI.
“But if they don’t want to come to India, it’s not our problem. Bangladesh has already been invited to participate in the case Pakistan doesn’t come, but we will have to wait for two more days to get the confirmation,” he added. “Neither Pakistan nor Bangladesh have confirmed anything to us till now. But Bangladesh are likely replacement for Pakistan,” the official said.
What Asia Cup 2025 hockey mean to all teams?
The Asia Cup 2025 will serve as a qualifying tournament for the 2026 Hockey World Cup in the Netherlands and Belgium. Apart from host India, the other participating teams in the Asia Cup are China, Japan, Malaysia, South Korea, Oman, and Chinese Taipei. South Korea is the defending champion of the Asia Cup 2025.
Earlier, the HI president Dilip Tirkey had welcomed the move by the Government of India to allow Pakistan to participate in the tournament. “If that is the case (allowing Pakistan in the Asia Cup), then it’s great news for hockey in the country. Since India is hosting both the Asia Cup and Junior World Cup, and Pakistan’s participation in both these tournaments is great news for the fans,” Tirkey said.
That Bumble Inc. founder Whitney Wolfe Herd couldn’t participate in her own biopic is precisely what drew actor and producer Lily James to it. The filmmakers didn’t even reach out to Wolfe Herd because the project tackled material that was covered by a nondisclosure agreement.
“Part of why I wanted to make this movie is to explore how NDAs are weaponized against women,” James says in a phone call, her homegrown British accent a stark contrast to the cheery American one she assumes as the bubbly tech founder in Swiped. The NDA in question was part of Wolfe Herd’s 2014 settlement with Tinder and parent IAC/InterActiveCorp, now IAC Inc., which she’d sued for discrimination and sexual harassment. “In a way this film becomes a form of reclamation not just for Whitney but for women who have been told to keep quiet,” James says.
Abreu Advogados provided legal advice to the Veolia Group in the limited tender by prior qualification, a contract that secured it the management of the Energy Recovery Plant of Lipor, an entity representing eight municipalities in the Greater Porto area, for a further 15 years.
This project is based on a strategy of decarbonisation, energy efficiency and digitalisation, in line with the sustainability goals of the intermunicipal entity, which serves around one million inhabitants in the municipalities of Espinho, Gondomar, Maia, Matosinhos, Porto, Póvoa de Varzim, Valongo and Vila do Conde.
Lipor’s Energy Recovery Plant processes around 390,000 tonnes of urban waste annually, converting it into enough electricity to supply approximately 150,000 people. In addition to continuing the operation and maintenance of the Energy Recovery Plant, the aim is for the plant to become one of the most decarbonised waste-to-energy facilities in Portugal.
Among other initiatives, the contract provides for studies to install a solar photovoltaic unit for self-consumption, a carbon capture unit with the potential to reduce CO₂ emissions by more than 90%, and the diversification of the energy produced, moving from the current exclusively electrical production to the potential inclusion of thermal energy.
Lipor also plans to explore the establishment of an energy community, moving from a regulated tariff to a market tariff that will directly benefit the municipalities served by the plant, closing the cycle of transforming waste into resources with economic benefits.
Advisors
Abreu Advogados’ advice consisted of support throughout the contract formation process, from the application phase, with assistance in reviewing documents and defining the structure of the Candidate, to the proposal phase, with assistance in supporting documentation and analysing competing proposals. After the adjudication, Abreu supported Veolia in the qualification phase of the competing group and proceeded to set up an SPV to be assigned to the operation. The intervention of the Competition Authority was also analysed in view of the operation to be carried out.
The team involved in the operation was led by Mafalda Teixeira de Abreu and supported by Marta Romano de Castro, Sónia Gemas Donário, Guilherme Mata da Silva and Catarina Miguéis Picado.
Jaishankar D, Shukla D. Genital herpes: insights into sexually transmitted infectious disease. Microb Cell. 2016;3(9):438–50.
PubMed
PubMed Central
Google Scholar
Drago F, Aragone MG, Lugani C, Rebora A. Cytomegalovirus infection in normal and immunocompromised humans A review. Dermatology. 2000;200(3):189–95.
PubMed
Google Scholar
Mourinha V, Costa S, Urzal C, Guerreiro F. Lipschütz ulcers: uncommon diagnosis of vulvar ulcerations. BMJ Case Rep. 2016;2016:bcr2015214338.
PubMed
PubMed Central
Google Scholar
Heyns CF, Fisher M. The urological management of the patient with acquired immunodeficiency syndrome. BJU Int. 2005;95(5):709–16.
PubMed
Google Scholar
Berntsson M, Dubicanac L, Tunbäck P, Ellström A, Löwhagen GB, Bergström T. Frequent detection of cytomegalovirus and Epstein-Barr virus in cervical secretions from healthy young women. Acta Obstet Gynecol Scand. 2013;92(6):706–10.
PubMed
Google Scholar
Pyöriä L, Jokinen M, Toppinen M, Salminen H, Vuorinen T, Hukkanen V, et al. HERQ-9 Is a New Multiplex PCR for Differentiation and Quantification of All Nine Human Herpesviruses. mSphere. 2020;5(3):e00265-20.
PubMed
PubMed Central
Google Scholar
Lehtinen M, Apter D, Baussano I, Eriksson T, Natunen K, Paavonen J, et al. Characteristics of a cluster-randomized phase IV human papillomavirus vaccination effectiveness trial. Vaccine. 2015;33(10):1284–90.
PubMed
Google Scholar
Lehtinen M, Öhman H, Korhonen S, Eriksson T, Kares S, Natunen K, et al. Effectiveness of Chlamydia trachomatis screening: population-based trial. In: Proceedings of the Fourteenth International Symposium on Human Chlamydial Infections. Netherlands: Gildeprint; 2018. p. 191–4.
Söderlund-Strand A, Carlson J, Dillner J. Modified general primer PCR system for sensitive detection of multiple types of oncogenic human papillomavirus. J Clin Microbiol. 2009;47(3):541–6.
PubMed
PubMed Central
Google Scholar
Söderlund-Strand A, Dillner J. High-throughput monitoring of human papillomavirus type distribution. Cancer Epidemiol Biomarkers Prev. 2013;22(2):242–50.
PubMed
Google Scholar
Jensen JS, Björnelius E, Dohn B, Lidbrink P. Use of TaqMan 5’ nuclease real-time PCR for quantitative detection of Mycoplasma genitalium DNA in males with and without urethritis who were attendees at a sexually transmitted disease clinic. J Clin Microbiol. 2004;42(2):683–92.
PubMed
PubMed Central
Google Scholar
Korhonen S, Hokynar K, Eriksson T, Natunen K, Paavonen J, Lehtinen M, et al. The prevalence of HSV, HHV-6, HPV and Mycoplasma genitalium in Chlamydia trachomatis positive and Chlamydia trachomatis negative urogenital samples among young women in Finland. Pathogens. 2019;8(4):276.
PubMed
PubMed Central
Google Scholar
Nummi M, Mannonen L, Puolakkainen M. Development of a multiplex real-time PCR assay for detection of Mycoplasma pneumoniae, Chlamydia pneumoniae and mutations associated with macrolide resistance in Mycoplasma pneumoniae from respiratory clinical specimens. Springerplus. 2015;4:684.
PubMed
PubMed Central
Google Scholar
Puhakka L, Sarvikivi E, Lappalainen M, Surcel HM, Saxen H. Decrease in seroprevalence for herpesviruses among pregnant women in Finland: cross-sectional study of three time points 1992, 2002 and 2012. Infect Dis. 2016;48(5):406–10.
Google Scholar
Koelle DM, Benedetti J, Langenberg A, Corey L. Asymptomatic reactivation of herpes simplex virus in women after the first episode of genital herpes. Ann Intern Med. 1992;116(6):433–7.
PubMed
PubMed Central
Google Scholar
Wald A, Zeh J, Selke S, Ashley RL, Corey L. Virologic characteristics of subclinical and symptomatic genital herpes infections. N Engl J Med. 1995;333(12):770–5.
PubMed
Google Scholar
Kortekangas-Savolainen O, Orhanen E, Puodinketo T, Vuorinen T. Epidemiology of genital herpes simplex virus type 1 and 2 infections in southwestern Finland during a 10-year period (2003–2012). Sex Transm Dis. 2014;41(4):268–71.
PubMed
Google Scholar
Tuokko H, Bloigu R, Hukkanen V. Herpes simplex virus type 1 genital herpes in young women: current trend in Northern Finland. Sex Transm Infect. 2014;90(2):160.
PubMed
Google Scholar
Agut H, Bonnafous P, Gautheret-Dejean A. Laboratory and clinical aspects of human herpesvirus 6 infections. Clin Microbiol Rev. 2015;28(2):313–35.
PubMed
PubMed Central
Google Scholar
Verbeek R, Vandekerckhove L, Van Cleemput J. Update on human herpesvirus 7 pathogenesis and clinical aspects as a roadmap for future research. J Virol. 2024;98(6):e0043724.
PubMed
Google Scholar
Biganzoli P, Frutos MC, Venezuela F, Mosmann J, Kiguen A, Pavan J, et al. Detection of human herpesvirus 6 (HHV-6) and human herpesvirus 7 (HHV-7) DNA in endocervical samples from a positive and negative HPV woman of Córdoba, Argentina. J Clin Pathol. 2020;73(1):30–4.
PubMed
Google Scholar
Baillargeon J, Piper J, Leach CT. Epidemiology of human herpesvirus 6 (HHV-6) infection in pregnant and nonpregnant women. J Clin Virol. 2000;16(3):149–57.
PubMed
Google Scholar
Okuno T, Oishi H, Hayashi K, Nonogaki M, Tanaka K, Yamanishi K. Human herpesviruses 6 and 7 in cervixes of pregnant women. J Clin Microbiol. 1995;33(7):1968–70.
PubMed
PubMed Central
Google Scholar
Ohashi M, Yoshikawa T, Ihira M, Suzuki K, Suga S, Tada S, et al. Reactivation of human herpesvirus 6 and 7 in pregnant women. J Med Virol. 2002;67(3):354–8.
PubMed
Google Scholar
Kaasinen E, Aavikko M, Vahteristo P, Patama T, Li Y, Saarinen S, et al. Nationwide registry-based analysis of cancer clustering detects strong familial occurrence of Kaposi sarcoma. PLoS ONE. 2013;8(1): e55209.
PubMed
PubMed Central
Google Scholar
Garib G, Hughey LC, Elmets CA, Cafardi JA, Andea AA. Atypical presentation of exophytic herpes simplex virus type 2 with concurrent cytomegalovirus infection: a significant pitfall in diagnosis. Am J Dermatopathol. 2013;35(3):371–6.
PubMed
PubMed Central
Google Scholar
Ito K, Okuno T, Sawada A, Sakai K, Kato Y, Muro K, et al. Recurrent aphthous stomatitis caused by cytomegalovirus, herpes simplex virus, and Candida species in a kidney transplant recipient: a case report. Transplant Proc. 2019;51(3):993–7.
PubMed
Google Scholar
Chen CH, Lan CCE. Cutaneous cytomegalovirus and herpes simplex virus coinfection presented as refractory buttock ulcer in a patient with anti-interferon-γ syndrome. J Dermatol. 2024;51(2):e47–8.
PubMed
Google Scholar
Humar A, Asberg A, Kumar D, Hartmann A, Moussa G, Jardine A, et al. An assessment of herpesvirus co-infections in patients with CMV disease: correlation with clinical and virologic outcomes. Am J Transplant. 2009;9(2):374–81.
PubMed
Google Scholar
Hatayama Y, Hashimoto Y, Motokura T. Frequent co-reactivation of Epstein-Barr virus in patients with cytomegalovirus viremia under immunosuppressive therapy and/or chemotherapy. J Int Med Res. 2020;48(11):300060520972880.
PubMed
Google Scholar
Kluger N, Puisto R, Suhonen J, Mazur W. Disseminated varicella zoster virus and herpes simplex virus co-infection in a lung-transplant recipient. Ann Dermatol Venereol. 2022;149(1):71–3.
PubMed
Google Scholar
Deka S, Vanover J, Dessus-Babus S, Whittimore J, Howett MK, Wyrick PB, et al. Chlamydia trachomatis enters a viable but non-cultivable (persistent) state within herpes simplex virus type 2 (HSV-2) co-infected host cells. Cell Microbiol. 2006;8(1):149–62.
PubMed
Google Scholar
Prusty BK, Böhme L, Bergmann B, Siegl C, Krause E, Mehlitz A, et al. Imbalanced oxidative stress causes chlamydial persistence during non-productive human herpes virus co-infection. PLoS ONE. 2012;7(10): e47427.
PubMed
PubMed Central
Google Scholar
Kienka T, Varga MG, Caves J, Smith JS, Sivaraman V. Epstein-Barr virus, but not human cytomegalovirus, is associated with a high-grade human papillomavirus-associated cervical lesions among women in North Carolina. J Med Virol. 2019;91(3):450–6.
PubMed
Google Scholar
Higgins CD, Swerdlow AJ, Macsween KF, Harrison N, Williams H, McAulay K, et al. A study of risk factors for acquisition of Epstein-Barr virus and its subtypes. J Infect Dis. 2007;195(4):474–82.
PubMed
Google Scholar
Coonrod D, Collier AC, Ashley R, DeRouen T, Corey L. Association between cytomegalovirus seroconversion and upper genital tract infection among women attending a sexually transmitted disease clinic: a prospective study. J Infect Dis. 1998;177(5):1188–93.